ClinicalTrials.Veeva

Menu

Acute Effect of Photobiomodulation on Quadriceps Muscle Strength in Patients With Chronic Kidney Failure on Hemodialysis

F

Federal University of Health Science of Porto Alegre

Status

Completed

Conditions

Renal Dialysis
Renal Insufficiency, Chronic

Treatments

Other: Photobiomodulation

Study type

Interventional

Funder types

Other

Identifiers

NCT05881772
Laser_HD

Details and patient eligibility

About

Chronic kidney disease (CKD) consists of kidney damage and progressive and irreversible loss of kidney function. The aim of this study is to evaluate the acute effect of different doses of photobiomodulation therapy on quadriceps isometric muscle strength, pain and muscle fatigue of lower limbs and to establish the ideal dose for patients with CKD on hemodialysis. Patients will be submitted to application of photobiomodulation therapy in the quadriceps muscle. Immediately after, the maximum isometric strength test of the quadriceps will be performed.

Full description

Chronic kidney disease (CKD) consists of kidney damage and progressive and irreversible loss of kidney function. In the most advanced stage of the disease the patients require hemodialysis (HD) and present alterations such as: sarcopenia, cardiovascular disorders, increased systemic inflammation, muscle weakness and fatigue. These factors negatively affect the individual's functionality, impacting the increase in hospitalization and mortality rates. Photobiomodulation (FBM) has shown positive results in different populations on improving performance during exercise, reducing fatigue and markers of muscle damage. The aim of this study is to evaluate the acute effect of FBM therapy on quadriceps muscle strength, pain and muscle fatigue in patients with CKD on HD and to establish the ideal therapeutic dose. Patients will be submitted to application of four applications with different doses of FBM (30J, 60J, 90J and placebo) in the quadriceps muscle, in random order and one week interval between them for washout. Patients and evaluators will be blinded to the intervention protocol. The following assessments will be performed prior to FBM: subjective perception of exertion (by modified Borg scale), muscle fatigue (by analysis of blood lactate) and pain perception (by numeric pain scale). After the FBM application, the maximum isometric strength test of the quadriceps will be performed by dynamometry. Immediately after performing the strength test, all assessments will be repeated.

Enrollment

10 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with CKD on HD for a period ≥ 3 months;
  • Age between 18-80 years old;
  • Patients of both sexes;
  • Dialysis with a weekly frequency of 3 times/week;
  • Adequate urea clearance rate (Kt/V ≥ 1.2 or URR ≥65%).

Exclusion criteria

  • Cognitive dysfunction that prevents the performance of the assessments, as well as inability to understand and sign the informed consent form;
  • Epidermal lesions at the site of application of photobiomodulation therapy;
  • Patients with recent stroke sequelae (three months);
  • Recent acute myocardial infarction (two months);
  • Uncontrolled hypertension (SBP>230 mmHg and DBP>120 mmHg);
  • HF grade IV according to the New York Heart Association or decompensated;
  • Unstable angina;
  • Peripheral vascular changes in lower limbs such as deep venous thrombosis;
  • Disabling osteoarticular or musculoskeletal disease;
  • Uncontrolled diabetes (blood glucose > 300mg/dL);
  • Febrile state and/or infectious disease;
  • Systemic lupus erythematosus;
  • Patients undergoing cancer treatment.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

10 participants in 4 patient groups, including a placebo group

Experimental 1
Active Comparator group
Description:
It will be applied a dose of 30J (180J per leg) of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence Maxx, São Paulo, Brazil) on quadriceps muscle.
Treatment:
Other: Photobiomodulation
Experimental 2
Active Comparator group
Description:
It will be applied a dose of 60J (360J per leg) of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence Maxx, São Paulo, Brazil) on quadriceps muscle.
Treatment:
Other: Photobiomodulation
Experimental 3
Active Comparator group
Description:
It will be applied a dose of 90J (540J per leg) of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence Maxx, São Paulo, Brazil) on quadriceps muscle.
Treatment:
Other: Photobiomodulation
Placebo group
Placebo Comparator group
Description:
The placebo treatment will be performed with the equipment HTM® (model Fluence Maxx, São Paulo, Brazil) turned off.
Treatment:
Other: Photobiomodulation

Trial contacts and locations

1

Loading...

Central trial contact

Jociane Schardong, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems